Dermatology Patients Pleased With Telehealth Options
TUESDAY, Feb. 9, 2021 -- Dermatology patients have been overall very pleased with teledermatology consultations during the COVID-19 pandemic, according to a study published online Jan. 14 in the Journal of Drugs in Dermatology.
Samuel Yeroushalmi, from the George Washington University School of Medicine and Health Sciences in Washington, D.C., and colleagues conducted an online survey of 168 patients who completed telehealth appointments during the COVID-19 pandemic.
The researchers found that the most common reasons for making a telehealth appointment were for a new rash (11.6 percent), eczema (9.8 percent), and psoriasis (9.1 percent). Cited benefits of telehealth included time efficiency (81.1 percent), not requiring transportation (74.2 percent), and maintaining social distancing (73.6 percent). Complaints about telehealth included lack of physical touch (26.8 percent) and feeling they received an inadequate assessment (15.7 percent). Only 9.9 percent of patients reported that they were unlikely to undertake another telehealth visit, and 6.9 percent would not recommend a telehealth visit to others.
"Overall, telemedicine represents an effective and safe vehicle for delivering care, especially during a global pandemic," the authors write.
© 2021 HealthDay. All rights reserved.
Posted: February 2021
Further Support and Information on COVID-19
Read this next
MONDAY, Feb. 22, 2021 -- A clear bimodal age pattern exists in psoriasis onset, and prevalence shows an increasing trend with age until 60 or 70 years, according to a review...
WEDNESDAY, Feb. 17, 2021 -- Overall pregnancy and live birth outcomes are similar for women with psoriasis and for the general population, according to a study published online...
TUESDAY, Feb. 2, 2021 -- Skin infections in the first two years of life are associated with pediatric psoriasis, according to a study recently published in the Journal of the...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.